New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
06:34 EDTALXNAlexion sees FY13 non-GAAP EPS $2.82-$2.92, consensus $2.81
Sees FY13 $1.49B-$1.51B, consensus $1.49B. R&D expenses are expected to be in the range of $285M-$295M, and SG&A expenses in the range of $425M-$435M. The non-GAAP effective tax rate, reported on a cash tax liability basis, is expected to be in the range of 7%-9%.
News For ALXN From The Last 14 Days
Check below for free stories on ALXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
07:52 EDTALXNAlexion says Soliris production not interrupted by FDA facility inspection
Subscribe for More Information
06:31 EDTALXNAlexion initiates multinational registration trial of eculizumab
Subscribe for More Information
August 18, 2014
07:57 EDTALXNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use